IgG-like bispecific T-cell–redirecting antibody that binds FcRH5 on myeloma/plasma cells and CD3 on T cells, inducing T cell–mediated cytotoxicity.
IgG-like bispecific antibody that binds FCRH5 on myeloma/plasma cells and CD3 on T cells, crosslinking T cells to tumor cells to activate TCR/CD3 signaling and induce T cell–mediated cytotoxic lysis of FCRH5-expressing cells.
Bispecific antibody links CD3 on T cells to FCRH5 on target cells, forming an immune synapse and activating T-cell cytotoxicity (perforin/granzyme-mediated lysis) of FCRH5+ cells.
IgG-like bispecific T-cell engager targeting BCMA on myeloma cells and CD3, triggering T-cell activation and lysis of tumor cells.
IgG-like bispecific antibody that binds CD3 on T cells and BCMA on malignant plasma cells, cross-linking T cells with tumor cells to activate cytotoxic T-lymphocyte responses and induce lysis of BCMA-expressing myeloma cells.
Bispecific binding to CD3 and BCMA cross-links T cells with BCMA+ cells, activating CTLs to form an immune synapse and kill targets via perforin/granzyme-mediated lysis/apoptosis.
Rabbit polyclonal anti-thymocyte globulin that depletes T cells to prevent rejection and GVHD.
Rabbit polyclonal anti-thymocyte IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis, producing immunosuppression to prevent rejection and GVHD.
Polyclonal anti-thymocyte IgG binds CD7 on T cells and induces complement-dependent cytotoxicity and Fc-mediated ADCC (and apoptosis), depleting CD7+ cells.
A bispecific T-cell engager (BiTE) antibody construct that binds CD19 on B cells and CD3 on T cells to redirect cytotoxic T cells to eliminate CD19+ B cells, reducing pathogenic B cells/plasmablasts and autoantibody production.
Blinatumomab is a BiTE antibody that simultaneously binds CD19 on B cells and CD3 on T cells, bringing T cells into contact with CD19+ B cells to activate cytotoxic T-cell killing (perforin/granzyme), leading to rapid depletion of pathogenic B cells/plasmablasts and reduced autoantibody production.
Blinatumomab bridges CD3+ T cells to CD19+ cells, inducing immune synapse formation and T-cell cytotoxicity via perforin/granzyme-mediated apoptosis of CD19-expressing cells.
IgG1 monoclonal antibody against HER2 domain II that blocks HER2 dimerization (especially HER2:HER3), suppressing downstream PI3K/AKT and MAPK signaling; also mediates ADCC.
Humanized IgG1 monoclonal antibody that binds HER2 extracellular domain II, blocking HER2 dimerization (especially HER2:HER3), thereby inhibiting downstream PI3K/AKT and MAPK signaling and reducing tumor cell proliferation; also mediates antibody-dependent cellular cytotoxicity (ADCC).
Binds HER2 on target cells and engages Fcγ receptor–bearing effector cells via its IgG1 Fc to trigger antibody‑dependent cellular cytotoxicity (ADCC), killing HER2+ cells; also inhibits HER2 signaling, which can promote apoptosis.